COVID-19 IgG, Qualitative by CIA
Also known as: COV19QUALG
Use
The test is used for the qualitative detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2, which develop in response to natural infection with the virus. These antibodies do not form as a result of vaccination against COVID-19. The test can aid in determining past exposure to the virus but is not recommended for assessing the immune response to vaccination. Negative results do not rule out SARS-CoV-2 infection, and the test should not be used as the sole basis to diagnose or exclude infection or to inform infection status.
Special Instructions
The test requires the submission of a Public Health Demographics Form if complete demographic information is not transmitted to ARUP. The preferred specimen container for submission is the ARUP Standard Transport Tube (ARUP Item# 15824).
Limitations
The test should not be used for screening donated blood. It is under FDA Emergency Use Authorization and should not be the sole basis used to diagnose or exclude SARS-CoV-2 infection. False-positive results can occur due to past or present infection with non-SARS-CoV-2 strains such as HKU1, NL63, OC43, or 229E. In low prevalence settings, false positives are possible even with a high specificity rate of the test. Follow-up testing with a molecular diagnostic test should be considered for individuals in contact with the virus.
New York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 94563-4
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated transport
Causes for Rejection
Grossly hemolyzed, grossly icteric, or severely lipemic specimens. Postmortem specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 1 week |
| Frozen | 1 month |